Trevie, Inc.   Report issue

For profit Phase 2
Founded: Los Angeles CA United States (1972)

Organization Overview

First Clinical Trial
2018
NCT03289299
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Trevie, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Smoldering Multiple Myeloma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 4